Foto del docente

Fausto Castagnetti

Professore associato

Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale

Settore scientifico disciplinare: MED/15 MALATTIE DEL SANGUE

Pubblicazioni

Zaccaria A; Testoni N; Valenti AM; Luatti S; Tonelli M; Marzocchi G; Cipriani R; Baldazzi C; Giannini B; Stacchini M; Gamberini C; Castagnetti F; Rosti G; Azzena A; Cavazzini F; Cianciulli AM; Dalsass A; Donti E; Giugliano E; Gozzetti A; Grimoldi MG; Ronconi S; Santoro A; Spedicato F; Zanatta L; Baccarani M, Chromosome abnormalities additional to the Philadelphia chromosome at the diagnosis of chronic myelogenous leukemia: pathogenetic and prognostic implications., «CANCER GENETICS AND CYTOGENETICS», 2010, 199, pp. 76 - 80 [articolo]

Rosti G; Castagnetti F; Gugliotta G; Palandri F; Martinelli G; Baccarani M., Dasatinib and nilotinib in imatinib-resistant Philadelphia-positive chronic myelogenous leukemia: a 'head-to-head comparison., «LEUKEMIA & LYMPHOMA», 2010, 51, pp. 583 - 591 [articolo]

Castagnetti F; Testoni N;Luatti S; Marzocchi G; Mancini M; Kerim S; Giugliano E; Albano F; Cuneo A;Abruzzese E; Martino B; Palandri F; Amabile M; Iacobucci I; Alimena G; Pane F; Martinelli G; Saglio G; Baccarani M; Rosti G, Deletionsof the derivative chromosome 9 do not influence the response and the outcomeof chronic myeloid leukemia in early chronic phase treated with imatinibmesylate: GIMEMA CML Working Party analysis, «JOURNAL OF CLINICAL ONCOLOGY», 2010, 28(16), pp. 2748 - 2754 [articolo]

Carpiuc K.T.; Rosti G.; Castagnetti F.; Treur M.; Stephens J., Indirect comparisons of second-generation tyrosine kinase inhibitors in CML: case study using baseline population characteristics., «ONCOTARGETS AND THERAPY», 2010, 3, pp. 205 - 210 [articolo]

Palandri F; Polverelli N; Ottaviani E; Castagnetti F; Baccarani M; Vianelli N., Long-term follow-up of essential thrombocythemia in young adults: treatment strategies, major thrombotic complications and pregnancy outcomes. A study of 76 patients., «HAEMATOLOGICA», 2010, 95, pp. 1038 - 1040 [articolo]

Breccia M; Palandri F; Iori AP; Colaci E; Latagliata R; Castagnetti F; Torelli GF; Usai S; Valle V; Martinelli G; Rosti G; Foà R; Baccarani M; Alimena G., Second-generation tyrosine kinase inhibitors before allogeneic stem cell transplantation in patients with chronic myeloid leukemia resistant to imatinib, «LEUKEMIA RESEARCH», 2010, 34(2), pp. 143 - 147 [articolo]

Palandri F; Castagnetti F; Iacobucci I; Martinelli G; Amabile M; Gugliotta G; Poerio A; Testoni N; Breccia M; Bocchia M; Crugnola M; Rege-Cambrin G; Martino B; Pierri I; Radaelli F; Specchia G; Pane F; Saglio G; Rosti G; Baccarani M, The response to imatinib and interferon-alpha is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phase., «HAEMATOLOGICA», 2010, 95, pp. 1415 - 1419 [articolo]

Baccarani M; Rosti G; Castagnetti F; Haznedaroglu I; Porkka K; Abruzzese E; Alimena G; Ehrencrona H; Hjorth-Hansen H; Kairisto V; Levato L; Martinelli G; Nagler A; Nielsen JL; Ozbek U; Palandri F; Palmieri F; Pane F; Rege-Cambrin G; Russo D; Specchia G; Testoni N; Weiss-Bjerrum O; Saglio G; Simonsson B., Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of patients with high risk, Philadelphia-positive, chronic myeloid leukaemia: a European LeukemiaNet study, «BLOOD», 2009, 113(19), pp. 504 - 4497 [articolo]

Piccaluga PP; Sabattini E; Bacci F; Agostinelli C; Righi S; Salmi F; Testoni N; Paolini S; Castagnetti F; Martinelli G; Falini B; Pileri SA., Cytoplasmic mutated nucleophosmin (NPM1) in blast crisis of chronic myeloid leukaemia., «LEUKEMIA», 2009, 23, pp. 1370 - 1371 [articolo]

Baldazzi C; Luatti S; Marzocchi G; Stacchini M; Gamberini C; Castagnetti F; Palandri F; Rosti G; Baccarani M; Testoni N., Emergence of clonal chromosomal abnormalities in Philadelphia negative hematopoiesis in chronic myeloid leukemia patients treated with nilotinib after failure of imatinib therapy, «LEUKEMIA RESEARCH», 2009, 33, pp. e218 - e220 [articolo]

Palandri F; Testoni N; Luatti S; Marzocchi G; Baldazzi C; Stacchini M; Castagnetti F; Breccia M; Specchia G; Pane F; Saglio G; Martinelli G; Baccarani M; Rosti G., Influence of additional cytogenetic abnormalities on the response and survival in late chronic phase chronic myeloid leukemia patients treated with imatinib: long-term results., «LEUKEMIA & LYMPHOMA», 2009, 50(1), pp. 114 - 118 [articolo]

Lemoli RM; Salvestrini V; Bianchi E; Bertolini F; Fogli M; Amabile M; Tafuri A; Salati S; Zini R; Testoni N; Rabascio C; Rossi L; Martin-Padura I; Castagnetti F; Marighetti P; Martinelli G; Baccarani M; Ferrari S; Manfredini R., Molecular and functional analysis of the stem cell compartment of chronic myelogenous leukemia reveals the presence of a CD34- cell population with intrinsic resistance to imatinib., «BLOOD», 2009, 114(25), pp. 5191 - 5200 [articolo]

Rosti G; Palandri F; Castagnetti F; Breccia M; Levato L; Gugliotta G; Capucci A; Cedrone M; Fava C; Intermesoli T; Cambrin GR; Stagno F; Tiribelli M; Amabile M; Luatti S; Poerio A; Soverini S; Testoni N; Martinelli G; Alimena G; Pane F; Saglio G; Baccarani M; GIMEMA CML Working Party., Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia., «BLOOD», 2009, 114, pp. 4933 - 4938 [articolo]

Palandri F; Castagnetti F; Soverini S; Poerio A; Gugliotta G; Luatti S; Amabile M; Martinelli G; Rosti G; Baccarani M., Pancreatic enzymes elevation in chronic myeloid leukemia patients treated with nilotinib after imatinib failure, «HAEMATOLOGICA», 2009, 94, pp. 1758 - 1761 [articolo]

Soverini S; Gnani A; Colarossi S; Castagnetti F; Abruzzese E; Paolini S; Merante S; Orlandi E; de Matteis S; Gozzini A; Iacobucci I; Palandri F; Gugliotta G; Papayannidis C; Poerio A; Amabile M; Cilloni D; Rosti G; Baccarani M; Martinelli G., Philadelphia-positive patients who already harbour imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors., «BLOOD», 2009, 114, pp. 2168 - 2171 [articolo]

Ultimi avvisi

Al momento non sono presenti avvisi.